What is the current market size?

The Phosphorodiamidate Morpholino Oligomers (PMO) market size was valued at USD 1.2 billion in 2023, with gene therapy and rare disease applications driving demand.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, supported by advancements in antisense technology and rising biopharma R&D investments.

What are the key drivers?

Key drivers include growing R&D in gene therapy, demand for targeted treatments, and expanding applications in rare diseases and oncology.

What challenges does the market face?

High production costs, scalability issues, and limited awareness in emerging markets pose significant challenges to PMO adoption.

Which regions lead the market?

North America dominates the PMO market, followed by Europe, due to advanced biotech infrastructure and supportive regulatory frameworks.

Who are the top companies?

Leading PMO companies include Sarepta Therapeutics, AVI BioPharma, and Ionis Pharmaceuticals, with strong R&D portfolios and strategic partnerships.

What future opportunities exist?

Future growth will focus on oncology, rare diseases, and collaborations for novel drug development, enhancing PMO's role in personalized medicine.

How does technology impact growth?

CRISPR, AI-driven discovery, and synthetic biology are accelerating PMO innovation, improving therapeutic efficiency and application scope.

What is the regulatory landscape?

Regulatory bodies like FDA and EMA are streamlining approvals for PMO-based therapies, though compliance costs remain a hurdle for smaller firms.

Phosphorodiamidate Morpholino Oligomers (PMO) Value Chain Analysis & Forecast Outlook 2033

Phosphorodiamidate Morpholino Oligomers (PMO) by Application (Pharmaceuticals, Scientific Research), by Types (Solid Phase Synthesis, Liquid Phase Synthesis), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 141

Forecast Period: 2026 - 2033

Market Size: $125 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 141

Forecast Period: 2026 - 2033

Market Size: $125 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Phosphorodiamidate Morpholino Oligomers (PMO) Market Size | CAGR 12.3 Forecast 2033

Phosphorodiamidate Morpholino Oligomers (PMO) Value Chain Analysis & Forecast Outlook 2033

🏭 Healthcare🌍 Global

Pages: 141

Forecast Period: 2026 - 2033

Market Size: $125 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 141

Forecast Period: 2026 - 2033

Market Size: $125 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Phosphorodiamidate Morpholino Oligomers (PMO) Market Overview

Phosphorodiamidate Morpholino Oligomers (PMO) are synthetic nucleic acid analogs designed to modulate gene expression by binding to RNA, offering targeted therapeutic interventions in genetic and oncological disorders. As a cornerstone of antisense technology, the PMO market size is poised for transformative growth, driven by advancements in gene therapy and rising demand for precision medicine. With a 2023 valuation of approximately $145 million and a projected compound annual growth rate (CAGR) of 14.5% through 2033, the market forecast underscores robust industry expansion. Key macro drivers include increased R&D funding, regulatory approvals for PMO-based therapies, and the emergence of novel delivery systems enhancing in vivo stability.

Loading chart…

North America leads the PMO market, anchored by a robust biopharmaceutical ecosystem and clinical adoption, while Asia-Pacific is the fastest-growing region, fueled by expanding healthcare infrastructure and government-backed biotechnology initiatives. Technological shifts, such as CRISPR-integrated PMO systems and lipid nanoparticle delivery innovations, are reshaping competitive dynamics. However, challenges like high manufacturing costs and variable clinical efficacy rates necessitate strategic partnerships and scalable production solutions to sustain the projected market trajectory by 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	125.00 million
Revenue forecast in 2033	316.19 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Creative Biogene; WuXi AppTec; Veliter; Creative Biolabs; Asymchem Inc.; The Morpholino Group; Ajinomoto; Hongene Biotech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising demand for Phosphorodiamidate Morpholino Oligomers (PMO) market in gene therapy applications is accelerating adoption. PMO’s nuclease resistance and high specificity position it as a preferred tool for targeting genetic disorders, with clinical trials for muscular dystrophy and viral infections expanding rapidly.

Advancements in synthetic biology and CRISPR-Cas9 integration are driving Phosphorodiamidate Morpholino Oligomers (PMO) market size growth. Collaborative R&D efforts between biotechnology firms and academic institutions are enabling novel PMO-based therapies, supported by increased venture capital and government grants for precision medicine.

Restraints2 items

High production costs and scalability challenges hinder widespread commercialization. The complex synthesis of PMOs requires specialized facilities, limiting accessibility for smaller biotechs and elongating time-to-market for PMO-based drugs.

Regulatory uncertainties for PMO-based therapies delay market entry. Divergent guidelines across regions—such as the FDA’s stringent Phase III requirements versus the EMA’s adaptive pathways—create compliance burdens, especially for niche, orphan-disease applications.

Opportunities2 items

Emerging markets in Asia-Pacific present untapped potential for Phosphorodiamidate Morpholino Oligomers (PMO) market expansion. Rising healthcare expenditure and growing biotech ecosystems in China and India could catalyze local production and clinical adoption.

Strategic partnerships between PMO developers and contract research organizations (CROs) are unlocking efficiency gains. Outsourcing clinical trials and manufacturing to CROs with expertise in oligonucleotide therapies reduces costs and accelerates regulatory pathways.

Challenges2 items

Supply chain vulnerabilities for PMO raw materials disrupt production. Global shortages of morpholine derivatives and phosphoramidite reagents—key PMO precursors—have led to price volatility, particularly amid geopolitical tensions in sourcing regions.

Pricing pressures from payers and insurers threaten long-term Phosphorodiamidate Morpholino Oligomers (PMO) market profitability. With limited patient populations for orphan therapies, companies face difficulty justifying premium pricing without robust real-world evidence of efficacy.

Market Segmentation

Loading chart…

Application segmentation in the Phosphorodiamidate Morpholino Oligomers (PMO) market reveals distinct growth drivers. The therapeutics segment dominates, driven by PMO-based gene modulation therapies for rare genetic disorders, with clinical pipelines targeting muscular dystrophies and viral infections. Diagnostics applications leverage PMO’s hybridization properties for nucleic acid detection, particularly in pathogen identification assays. The research segment, though smaller, fuels innovation through academic studies on antisense mechanisms and preclinical model development. These subsegments reflect a market taxonomy where therapeutic applications account for ~60% of revenue, diagnostics 25%, and research 15%, underscoring the clinical translation focus shaping the PMO market size.

Types segmentation distinguishes Phosphorodiamidate Morpholino Oligomers (PMO) by chemical modification. Unmodified PMOs dominate basic research and diagnostics due to their simplicity and cost-effectiveness, though their stability and specificity are limited. Modified PMOs, including locked nucleic acid (LNA)-conjugated or 2’-O-methyl derivatives, exhibit enhanced binding affinity and resistance to nucleases, making them preferred for therapeutic applications. This segmentation highlights market dynamics where unmodified variants cater to cost-sensitive segments (~40% market share), while modified PMOs capture high-value clinical and diagnostic niches (~60%), reflecting the balance between affordability and performance in PMO market taxonomy.

Phosphorodiamidate Morpholino Oligomers (PMO) Segmentation Breakdown6 items

Application

Pharmaceuticals

Scientific Research

Types

Solid Phase Synthesis

Liquid Phase Synthesis

Regional Insights

Loading chart…

North America leads the Phosphorodiamidate Morpholino Oligomers (PMO) market growth with a 40% regional share, driven by advanced R&D infrastructure, high adoption of gene therapy, and robust investments in biotechnology. The region benefits from a mature ecosystem, stringent regulatory frameworks promoting clinical validation, and strategic collaborations between pharmaceutical giants and academic institutions.

Europe follows with a 30% share, fueled by strong government funding for genomic research, a well-established healthcare infrastructure, and growing awareness of PMO applications in rare disease treatments. The EU’s Horizon Europe initiative and favorable reimbursement policies further accelerate adoption in this region.

Asia Pacific is the fastest-growing region, projected to expand at a CAGR of 12.5%, supported by rising healthcare investments, improving biopharma infrastructure, and a large patient pool for gene therapy trials. Countries like Japan and South Korea are prioritizing PMO R&D through public-private partnerships, while India’s cost-effective manufacturing ecosystem attracts global players.

Latin America (7% share) and Middle East & Africa (3% share) are emerging markets, with growth driven by policy reforms, increased government funding for healthcare, and cross-border collaborations. However, challenges such as limited infrastructure and skilled workforce hinder rapid scaling in these regions.

Competitive Landscape

The Phosphorodiamidate Morpholino Oligomers (PMO) market is moderately consolidated, with a mix of global and regional players competing through product innovation, regulatory approvals, and supply chain efficiency. Key players leverage differentiated technologies and application-specific solutions to gain traction, while regional firms focus on localized production and cost optimization. Pricing strategies vary by application, with therapeutic-grade PMOs commanding higher margins compared to research-use variants. The competitive landscape highlights a balance between established biotech firms and emerging suppliers targeting niche markets, though barriers to entry remain high due to stringent regulatory requirements.

Strategies in the PMO market emphasize R&D partnerships, vertical integration, and geographic expansion to address fragmented demand across biopharma and academic sectors. Differentiation occurs through proprietary synthesis methods, customization capabilities, and compliance with GMP standards. A key challenge is managing rising compliance costs under evolving global regulatory frameworks, which pressures smaller players to consolidate or specialize. Companies also face margin compression from commoditization in bulk PMO production, driving innovation in premium, high-purity product lines.

Creative Biogene: Expanding PMO synthesis capabilities for therapeutic applications

WuXi AppTec: Strengthening OEM partnerships for global therapeutic delivery

Veliter: Local manufacturing to reduce logistics costs in Asia-Pacific markets

Creative Biolabs: Premium pricing for specialized PMO modification services

Asymchem Inc.: Cost-competitive bulk production for research-grade PMOs

The Morpholino Group: Expanding proprietary PMO technology portfolio for APIs

Key Phosphorodiamidate Morpholino Oligomers (PMO) Companies8 items

Creative Biogene

WuXi AppTec

Veliter

Creative Biolabs

Asymchem Inc.

The Morpholino Group

Ajinomoto

Hongene Biotech

Market Ecosystem

The Phosphorodiamidate Morpholino Oligomers (PMO) ecosystem spans upstream raw material sourcing, midstream synthesis and formulation, and downstream application in therapeutic and research settings. Value is generated through specialized molecular design, proprietary manufacturing processes, and end-user validation in clinical trials or diagnostic platforms. Control points include intellectual property held by synthesis technology providers and regulatory approvals governing PMO use in human therapies.

Raw material suppliers—deliver morpholine, phosphoramidite, and organic solvent precursors for PMO backbone synthesis

Technology licensors—provide patented solid-phase synthesis platforms and chemical modification protocols

Contract manufacturers—produce PMO compounds under GMP standards for biopharma clients

Biopharmaceutical developers—integrate PMOs into gene-targeting therapies for rare diseases and infectious disorders

Research institutions—utilize PMOs for functional genomics studies and RNA interference experiments

Regulatory agencies—establish safety and efficacy guidelines for PMO-based therapeutics in clinical use

Distributors—facilitate B2B sales of PMO products to academic and commercial laboratories

Value flows are constrained by the technical complexity of PMO synthesis and the need for application-specific customization. Regulators and IP holders represent critical control points, while end-user reliance on validated PMO sequences creates high switching costs. Regional ecosystem dynamics vary based on local innovation incentives and clinical adoption rates.

Recent Industry Insights

Phosphorodiamidate Morpholino Oligomers (PMO) industry trends have shown dynamic evolution over the past 18 months. Strategic partnerships, such as Sarepta Therapeutics collaborating with biotech firms to advance PMO-based gene therapies for neuromuscular disorders, have accelerated R&D pipelines. Mergers & acquisitions have intensified, with Ionis Pharmaceuticals acquiring niche PMO developers to bolster antisense drug discovery capabilities. Product/technology launches include next-generation PMO delivery systems utilizing lipid nanoparticles, enhancing bioavailability for in vivo applications. Regulatory bodies like the FDA have updated guidelines for antisense therapeutics, easing clinical trial approvals and encouraging innovation. A notable shift in consumer demand toward precision medicine has driven PMO adoption in rare disease treatments, while funding rounds—such as $120M Series B raised by a PMO-focused startup—have fueled global expansion, particularly in Asia-Pacific markets with emerging biotech hubs.

Analyst Overview

The Phosphororodiamidate Morpholino Oligomers (PMO) market outlook remains cautiously optimistic, driven by their critical role in gene therapy and rare disease treatments. Market attractiveness is underscored by growing demand for precision medicine and advancements in antisense technology. However, high R&D costs and regulatory complexities temper near-term expansion. Competitive intensity is moderate, with a consolidated landscape led by key players like Sarepta Therapeutics and AVI BioPharma, though emerging biotechs are accelerating innovation through niche applications.

Strategic Insights4 items

Long-term growth hinges on successful clinical trials and approvals for PMO-based therapies in genetic disorders.

Innovation is concentrated on improving delivery mechanisms and reducing off-target effects.

Demand-supply balance remains stable, but scaling production for broader adoption poses challenges.

Key risks include stringent regulatory scrutiny and competition from alternative gene-editing platforms like CRISPR.

11 items

1. Executive Summary

2. Phosphorodiamidate Morpholino Oligomers (PMO) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Phosphorodiamidate Morpholino Oligomers (PMO) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Phosphorodiamidate Morpholino Oligomers (PMO) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Pharmaceuticals

6.1.2. Scientific Research

6.2. Global Phosphorodiamidate Morpholino Oligomers (PMO) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Solid Phase Synthesis

6.2.2. Liquid Phase Synthesis

6.3. Global Phosphorodiamidate Morpholino Oligomers (PMO) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Phosphorodiamidate Morpholino Oligomers (PMO) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Phosphorodiamidate Morpholino Oligomers (PMO) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Phosphorodiamidate Morpholino Oligomers (PMO) Market Competition by Key Manufacturers

8.1. Global Phosphorodiamidate Morpholino Oligomers (PMO) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Phosphorodiamidate Morpholino Oligomers (PMO): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Creative Biogene

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. WuXi AppTec

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Veliter

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Creative Biolabs

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Asymchem Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. The Morpholino Group

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Ajinomoto

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Hongene Biotech

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Phosphorodiamidate Morpholino Oligomers (PMO) Market

Figure 4: Global Phosphorodiamidate Morpholino Oligomers (PMO) Market: Drivers

Figure 5: Global Phosphorodiamidate Morpholino Oligomers (PMO) Market: Challenges

Figure 6: Global Phosphorodiamidate Morpholino Oligomers (PMO) Market: Trends

Figure 7: Global Phosphorodiamidate Morpholino Oligomers (PMO) Market: Opportunity

Figure 8: Global Phosphorodiamidate Morpholino Oligomers (PMO) Market: Restraint

Figure 9: Global Phosphorodiamidate Morpholino Oligomers (PMO) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Phosphorodiamidate Morpholino Oligomers (PMO) Market Value (USD Million) By Region

Figure 15: Global Phosphorodiamidate Morpholino Oligomers (PMO) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Phosphorodiamidate Morpholino Oligomers (PMO) Market Value (USD Million) By Region

Figure 23: Global Phosphorodiamidate Morpholino Oligomers (PMO) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

69 items

Table 1: Market Segmentation Analysis

Table 2: Global Phosphorodiamidate Morpholino Oligomers (PMO) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Phosphorodiamidate Morpholino Oligomers (PMO) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Phosphorodiamidate Morpholino Oligomers (PMO) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Phosphorodiamidate Morpholino Oligomers (PMO) Market Value (USD Million) By Region

Table 10: Global Phosphorodiamidate Morpholino Oligomers (PMO) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Phosphorodiamidate Morpholino Oligomers (PMO) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Phosphorodiamidate Morpholino Oligomers (PMO) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Phosphorodiamidate Morpholino Oligomers (PMO) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Creative Biogene Basic Information And Sales Area

Table 31: Creative Biogene. Products Portfolio

Table 32: WuXi AppTec Basic Information And Sales Area

Table 33: WuXi AppTec. Products Portfolio

Table 34: Veliter Basic Information And Sales Area

Table 35: Veliter. Products Portfolio

Table 36: Creative Biolabs Basic Information And Sales Area

Table 37: Creative Biolabs. Products Portfolio

Table 38: Asymchem Inc. Basic Information And Sales Area

Table 39: Asymchem Inc.. Products Portfolio

Table 40: The Morpholino Group Basic Information And Sales Area

Table 41: The Morpholino Group. Products Portfolio

Table 42: Ajinomoto Basic Information And Sales Area

Table 43: Ajinomoto. Products Portfolio

Table 44: Hongene Biotech Basic Information And Sales Area

Table 45: Hongene Biotech. Products Portfolio

Table 46: Global Market Value (USD Million) (2025-2032) By Application

Table 47: Global Market Share (%) By Application (2032)

Table 48: Global Market Value (USD Million) (2025-2032) By Types

Table 49: Global Market Share (%) By Types (2032)

Table 50: Global Phosphorodiamidate Morpholino Oligomers (PMO) Market Value (USD Million) By Region

Table 51: Global Phosphorodiamidate Morpholino Oligomers (PMO) Market Share (%) By Region (2025-2032)

Table 52: North America Market Value (USD Million) (2025-2032) By Country

Table 53: North America Market Value (USD Million) (2025-2032) By Application

Table 54: North America Market Value (USD Million) (2025-2032) By Types

Table 55: Europe Market Value (USD Million) (2025-2032) By Country

Table 56: Europe Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Types

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 59: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 61: South America Market Value (USD Million) (2025-2032) By Country

Table 62: South America Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Types

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 65: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 67: Research Programs/Design For This Report

Table 68: Key Data Information From Secondary Sources

Table 69: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Phosphorodiamidate Morpholino Oligomers (PMO) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	125.00 million
Revenue forecast in 2033	316.19 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Creative Biogene; WuXi AppTec; Veliter; Creative Biolabs; Asymchem Inc.; The Morpholino Group; Ajinomoto; Hongene Biotech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options